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INTRODUCTION 
 Historically, the pharmaceutical industry has always maintained and 
enjoyed strong financial earnings and business growth. Such healthy 
growth is not only made possible by launching new products but also by 
life-cycle management of older, existing products, which is playing an 
increasingly significant role. This aspect becomes even more important 
once the revenue drops significantly from the existing molecule due to 
patent protection expiry.  
 In the area of targeted delivery, the colonic region of the GI tract is 
the one that has been embraced by scientists and is being extensively 
investigated over the past two decades. Targeted delivery to the colon is 
being explored not only for local colonic pathologies, thus avoiding 
systemic effects of drugs or inconvenient and painful trans-colonic 
administration of drugs, but also for systemic delivery of drugs like proteins 
and peptides, which are otherwise degraded and or poorly absorbed in the 
stomach and small intestine but may be better absorbed from the more 
benign environment of the colon. This is also a potential site for the 
treatment of diseases sensitive to circadian rhythms such as asthma, 
angina and arthritis. Furthermore, there is urgent need for delivery to the 
colon of drugs that are reported to be absorbable in the colon, such as 
steroids, which would increase efficiency and enable reduction of the 
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required effective dose. The treatment of disorders of the large intestine, 
such as irritable bowel syndrome (IBS), colitis, crohn’s disease and colon 
disease, where it is necessary to attain a high concentration of the active 
agent, maybe efficiently achieved by colon-specific delivery.1 
 The oral route is considered to be most convenient for 
administration of drugs to patients. Oral administration of conventional 
dosage forms normally dissolves in the stomach fluid or intestinal fluid and 
absorb from these regions of the GIT depends upon the physicochemical 
properties of the drug. It is a serious drawback in conditions where 
localized delivery of the drugs in the colon is required or in conditions 
where a drug needs to be protected from the hostile environment of upper 
GIT. Dosage forms that deliver drugs into the colon rather than upper GIT 
proffers number of advantages. Oral delivery of drugs to the colon is 
valuable in the treatment of diseases of colon (ulcerative colitis, crohn's 
disease, carcinomas and infections) there by high local concentration can 
be achieved while minimizing side effects that occur because of release of 
drugs in the upper GIT or unnecessary systemic absorption. The colon is 
rich in lymphoid tissue, uptake of antigens into the mast cells of the colonic 
mucosa produces rapid local production of antibodies and this helps in 
efficient vaccine delivery. The colon is attracting interest as a site where 
poorly absorbed drug molecule may have an improved bioavailability. This 
region of the colon is recognized as having a somewhat less hostile 
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environment with less diversity and intensity of activity than the stomach 
and small intestine. Additionally, the colon has a longer retention time and 
appears highly responsive to agents that enhance the absorption of poorly 
absorbed drugs. Apart from retarding or targeting dosage forms, a reliable 
colonic drug delivery could also be an important starting position for the 
colonic absorption of perorally applied, undigested, unchanged and fully 
active peptide drugs. As the large intestine is relatively free of peptidases 
such special delivery systems will have a fair chance to get their drug 
sufficiently absorbed after peroral application. The simplest method for 
targeting of drugs to the colon is to obtain slower release rates or longer 
release periods by the application of thicker layers of conventional enteric 
coatings or extremely slow releasing matrices.2 
 The colon, as a site for drug delivery, offers distinct advantages on 
account of a near neutral pH, a much longer transit time, relatively low 
proteolytic enzyme activity, and a much greater responsiveness to 
absorption enhancers. These criteria favour this distal part of the 
gastrointestinal tract (GIT) as a site for the delivery of various drug 
molecules, including proteins and peptides. Colon-specific delivery 
systems should prevent the release of the drug in the upper-part of GIT 
and require a triggering mechanism to affect an abrupt release on 
reaching the colon. In the past, various primary approaches for colon-
specific delivery, such as pro-drugs, pH sensitive polymers, timed release 
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delivery systems, and microbially degraded delivery systems, have 
achieved limited success. The majority of these systems developed during 
the past decade, were based on pH and time dependent mechanisms with 
limited in-vivo evaluation. Minor variation in pH between the small intestine 
and the colon makes the pH-dependent systems less specific, in terms of 
targeted release in the colon. Time-dependent formulations predominantly 
depend on the transit time of the delivery system in the GIT. A major 
limitation with these systems is that in vivo variation of the small intestinal 
transit time may lead to release of the bioactive in the small intestine or 
terminal part of the colon. The pathophysiological state of an individual will 
have a significant impact on the performance of these time-dependent 
systems. Patients with irritable bowel syndrome and ulcerative colitis 
exhibited accelerated transit through different regions of the colon. 3 
Relevant drugs for colon-specific associated diseases are listed in table 1 
and colon-specific associated diseases are presented diagrammatically in 
figure1. 
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Fig. 1: Diagrammatical presentation of Colon associated diseases3 
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Table 1: Relevant drugs for colon-specific associated diseases3 
Target 
Sites 
Disease 
Conditions Symptoms 
Drugs and active 
agents 
Inflammatory 
Bowel Disease 
(Crohn’s 
disease) 
Diarrhea, Abdominal pain 
and cramping, blood in stool, 
ulcers, reduced appetite and 
weight loss 
Hydrocortisone, 
Budenoside, 
Prednisolone, 
Sulfasalazine 
Ulcerative colitis Inflammation in the rectum, rectal bleeding, rectal pain 
5-Amino salicylic acid, 
Sulfasalazine, 
Balsalazide, and 
mercaptopurine 
Irritable bowel 
syndrome 
Abdominal pain or cramping, 
a bloated feeling, flatulence, 
diarrhea or constipation — 
people with IBS may also 
experience alternating bouts 
of constipation and diarrhea, 
mucus in the stool 
Dicyclomine, Hyoscine, 
Propantheline, 
Cimetropium, Alosetron, 
Tegaserod 
Colorectal cancer
A change in bowel habits, 
narrow stools, rectal 
bleeding or blood in stool, 
persistent abdominal 
discomfort, such as cramps, 
gas or pain, abdominal pain 
with a bowel movement, 
unexplained weight loss 
5-Flourouracil, 
Leucovorin,and 
cetuximab 
Diverticulitis 
Formation of pouches 
(diverticula) on the outside of 
the colon due to bacterial 
infection 
Bactrim,Flagyl, Sulfatrim, 
Metronidazole 
Antibiotic 
associated 
colitis 
Overgrowth of Clostridium 
difficile and its subsequent 
toxin 
production 
clindamycin, broad-
spectrum penicillins (e.g., 
ampicillin, amoxicillin), 
and cephalosporins 
Topical 
/Local 
action 
Hirschsprung's 
disease 
Severe form of constipation 
in 
which bowel movement 
occurs 
only once or twice a week 
Metronidazole, 
Vancomycin, 
Loperamide,Botulinum 
toxin 
Systemic 
action Ulcerative colitis 
Ulcerative proctitis, 
pancolitis, fulminant 
colitis 
Prednisolone 
metasulfobenzoate, 
tixocortol pivalate, 
fluticasone propionate, 
beclomethasone 
 
 
Chapter 1  Introduction 
 7
 Colon-specific drug delivery has been approached by a number of 
methods exploiting changes in the physiological parameters along the 
gastrointestinal tract. The GIT transit time was utilized to formulate colon 
specific drug delivery systems which are so designed that their drug 
release is delayed to the time required for transiting drug from mouth 
cavity to distal part of small intestine i.e., ileum and subsequently drug 
release in the colon. Factors influencing the transit time of pharmaceutical 
dosage forms in the various regions of the gastrointestinal tract appear to 
depend on diet, gastrointestinal motility and physical activity of the person, 
fasted or fed state of the person. The change in pH along the 
gastrointestinal tract was also used to develop colon specific drug delivery 
systems by applying coatings that were intact at low pH and dissolved at 
neutral pH. The pH of the colon is however; often lower than the pH of the 
small intestine, which in turn may be as high as 8 or 9, resulting in a too 
early release of a drug. 
 A number of specific regional characters of the colon can be 
explored for site specific drug delivery to the colon. In the colon, an 
extensive growth of anaerobic micro organisms is observed. These colonic 
microflora produce a large number of hydrolytic as well as reductive 
enzymes which can potentially be utilized for colon-specific drug delivery. 
Prodrugs and coatings based on azo aromatic polymers and matrices 
containing azo aromatic cross-links are examples of systems that are 
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potentially degradable by reductive enzymes released by colonic bacteria. 
Apart from azo reductase enzyme release other polysaccharidases like 
glucosidases; glycosidases are also released by colonic microflora, which 
are responsible for the degradation of polysaccharides. Hence drug 
delivery systems based on polysaccharide can also be used for colon 
specific drug delivery.3 
FORMULATION TECHNOLOGIES FOR COLON SPECIFIC DRUG 
DELIVERY 
 Delivery systems for targeted delivery in the GIT could be 
categorized into four categories: (i) pH-based systems, (ii) Time-based 
delivery systems, (iii) Pressure-based systems, and (iv) Enzyme-based 
systems (prodrugs/coatings and matrices). 
pH-controlled drug delivery systems 
 Use of pH-dependent polymers is based on the difference in pH-
levels along the GIT. The polymers described as pH-dependent in colon 
specific delivery are insoluble at low pH levels but become increasingly 
soluble as pH rises. The pH in the GIT varies between and within 
individuals and also between healthy and patients which could lead to the 
failure of the system in the treatment of inflammatory bowel diseases. 
Moreover, during acute stage of inflammatory bowel disease colonic pH 
has been found to be significantly lower than the physiological pH. It must 
be also taken into consideration that, between the terminal ileum and the 
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distal colon, there is a slightly acidic region in the proximal colon, due to 
the fermentation of poly and oligosaccharides to short-chain fatty acids, 
which might affect drug release profiles and the reproducibility of drug 
release. Most commonly used pH-dependent coatings polymers are 
copolymers of methacrylic acid and methyl methacrylate containing 
carboxyl groups Eudragit S100 which is soluble above pH 7 and Eudragit 
L above pH 6 are mostly used polymers in targeted drug delivery to the 
colon. Eudragit S coatings have been used to target the anti-inflammatory 
drug 5-aminosalicylic acid in single-unit formulations on the colon.1 
 Recently, a new type of delivery system has been developed to 
delivery drug to the colon for the treatment of ulcerative colitis. 
EUDRACOL™ which is a combined pH- and time-based multi-unit dosage 
form which is already available for targeting drug to the colon. 
EUDRACOL™ consists of 5-aminosalicylic acid containing core which is 
then first coated with an aqueous dispersion of Eudragit RL: RS (2:8) and 
with a new pH-dependent anionic polymer Eudragit FS. The latter 
dissolves rapidly at pH above 7, triggering the onset of drug release in 
distal GIT. Eudragit RL/RS produce a slow release of drug from the 
pellets. The performance of this newly designed drug delivery system has 
been investigated in vitro as well as in vivo, and compared with solely pH-
dependent system.4 
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Time controlled drug delivery systems 
 Usually, time-dependent drug delivery systems are designed to 
deliver drugs after a lag of five to six hours. This approach is based upon 
the theory that the lag time equates to the time taken for the dosage form 
to reach the colon. The lag time is dependent on size of dosage form and 
gastric motility associated with the pathological condition of the individual. 
The residence times can vary from a few seconds to a number of hours. 
On the other hand the small intestine transit time is reported to be more 
consistent at three to four hours. Since the system is unable to sense and 
adapt to an individual’s condition, the approach clearly limits the utility. An 
example of such a dosage form would be an impermeable capsule body 
containing the drug, fitted with a hydrogel plug that is used to deliver the 
drug after a predetermined time. This dosage form, for example Pulsincap 
releases the drug once the hydrogel plug hydrates and swells in aqueous 
media and is ejected from the device, thereby allowing the release of the 
drug from the capsule.1 
 Systems based on time controlled release are identified as 
unsuitable for drug delivery in the colon for the treatment of inflammatory 
bowel diseases. The rationale behind all time-release delivery systems is 
valid provided that small intestine transit times remain constant. Changes 
in GI tract motility can significantly affect time-release drug delivery 
systems targeting the release of drugs to the colon. 4 
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Pressure controlled drug delivery systems  
 This novel delivery mechanism is utilised to initiate the release of 
the drug in the distal part of the gut. The muscular contractions of the gut 
wall generate pressure, which is responsible for grinding and propulsion of 
the intestinal contents. Pressure-sensitive drug formulations release the 
drug as soon as a certain pressure limit is exceeded. Polymers used for 
this topic form firm layers that are destroyed by an increase of the luminal 
pressure in the colon caused by peristaltic waves.  Disintegration of a 
pressure-controlled drug delivery system that consists of a gelatin capsule 
with an inner ethylcellulose coating is triggered by peristaltic waves, 
destroying the ethylcellulose film. As water ingresses into the core, the low 
substituted hydroxypropylcellulose will start swelling. The cap which is 
made of the water-insoluble ethylcellulose (EC) cannot persist the swelling 
pressure. The ethylcellulose cap disintegrates releasing the active drug 
from the container within the capsule. The most important factor for 
disintegration of the formulation is the thickness of the water-insoluble 
ethylcellulose film. 4 
Bacterially triggered drug delivery systems  
 The use of GI microflora as a mechanism of drug release in the 
colonic region has been of great interest to researchers in recent times. 
The colonic microflora produces a variety of enzymes that are not present 
or different from those in the stomach and the small intestine and could 
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therefore be used to deliver drugs to the colon after enzymatic cleavage of 
degradable formulation components or drug carrier bonds.`1 Most of the 
bacteria in the colon are anaerobic (95%) and facultative aerobic (5%). 
More than 400 bacterial species have been found in colon able to ferment 
complex polysaccharides. The carbohydrates are fermented into short 
chain fatty acids, carbon dioxide, hydrogen, methane and other products 
by the enzymes glycosidase and polysaccharidase. This concept could be 
divided into (i) the use of prodrugs breakdown by bacterial enzymes within 
the colon and (ii) use of tools (coatings/matrices) susceptible to colonic 
bacteria. 4 
Prodrugs  
 A prodrug is a pharmacologically inactive derivative of a parent 
molecule that requires some form of transformation in vivo to release the 
active drug at the target site. This approach involves covalent linkage 
between the drug and its carrier in such a manner that upon oral 
administration the moiety remains intact in the stomach and small 
intestine. The type of linkage that is formed between the drug and carrier 
would decide the triggering mechanism for the release of the drug in the 
colon. This biotransformation is carried out by a variety of enzymes, 
mainly of bacterial origin, present in the colon. The enzymes that are 
mainly targeted for colon drug delivery include azoreductase, β -
galactosidase, β-xylosidase, nitroreductase, glycosidase deaminase etc. 1 
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 Generally, a prodrug is successful as a colon drug carrier if it is 
hydrophilic and bulky, to minimise absorption from the upper GI tract and, 
once in the colon, it is converted into a more lipophilic drug molecule that 
is then available for absorption. 4 
 Certain drugs can be conjugated to different sugar moieties to form 
glycosides. The use of these azo compounds for colon targeting has been 
in the form of hydrogels as a coating material for coating the drug cores 
and as prodrugs. Sulphasalazine, which was used for the treatment of 
rheumatoid arthritis, was later known to have potential in the treatment of 
inflammatory bowel disease (IBD). This compound has an azo bond 
between 5-ASA and sulphapyridine. The azo bond split into mesalamine 
and sulfapyridine by bacterial azo reductase.2 
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Fig 2: Mechanism of microbial activation of sulfasalazine in the 
colon4 
 
Coatings and matrices  
 Polysaccharide-based formulations represent a relatively simple 
formulation concept because of its safety (most can be used without 
additional safety testing) if there are no chemical modifications to the 
polysaccharide. Moreover, polysaccharides are inexpensive and readily 
available in a variety of structures with a variety of properties. They can be 
easily modified chemically and bio chemically and are highly stable, safe, 
non-toxic, hydrophilic and gel forming and in addition biodegradable, which 
suggests their use in targeted drug delivery systems to the colon. Due to 
the high hydrophilicity polysaccharides possess high solubility and swelling 
in aqueous medium which lead to premature drug release in the upper GIT 
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when using polysaccharides solely as coating materials for colon drug 
delivery systems. To control the high swelling of polysaccharides 
hydrophobic polymers should be added in order to reduce the swelling, 
and subsequently to ensure that no or very low drug is released until it 
reaches the colon 4 
 The polysaccharides naturally occurring in plant (e.g., pectin, guar 
gum, inulin), animal (e.g.,chitosan, chondroitin sulphate), algal (e.g., 
alginates) or microbial (e.g., dextran) origin were studied for colon 
targeting. 2 
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PROFILE OF DRUG EMPLOYED IN  
THE STUDY 
INDOMETHACIN 10-13  
 
Chemistry 
 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H- Indole-3-acetic acid 
Category 
 Anti-inflammatory, Analgesic   
Description 
 White to pale yellow, crystalline powder, odourless  
Molecular weight 
 Indomethacin has a molecular weight of 357.79 g/mol 
Empirical formula 
 C19H16NO4Cl 
Solubility 
 Soluble in chloroform; slightly soluble in ethanol (95%) and 
practically insoluble in water  
Storage 
 Stored in well closed, light resistant containers  
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PHARMACODYNAMICS 
Mechanism of action 
 Indomethacin has prominent anti-inflammatory and analgesic-
antipyretic properties similar to those of the salicylates. Indomethacin is a 
more potent inhibitor of the cyclooxygenases than that of aspirin, but 
patient intolerance generally limits its use to short-term dosing. 
Indomethacin has analgesic properties distinct from its anti-inflammatory 
effects, and there is evidence for central and peripheral actions. 
 
Pharmacokinetics and metabolism 
 Oral Indomethacin has excellent bioavailability. Peak 
concentrations occur 1 to 2 hours after dosing. Indomethacin is 90% 
bound to plasma proteins and tissues. The concentration of the drug in the 
CSF is low, but its concentration in synovial fluid is equal to that in plasma 
within 5 hours of administration. Between 10% and 20% of indomethacin is 
excreted unchanged in the urine, partly by tubular secretion. The majority 
is converted to inactive metabolites. 
 
Half life 
 The half-life in plasma is variable, perhaps because of 
enterohepatic cycling, but averages about 2.5 hours. 
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Therapeutic uses 
• Indomethacin is effective for relieving joint pain, swelling, and 
tenderness, increasing grip strength, and decreasing the duration of 
morning stiffness.   
• It is estimated to be approximately 20 times more potent than 
aspirin. 
• It suppresses inflammation in a manner similar to steroids, but less 
side effects of sedation.  
• They are widely used for the treatment of inflammatory disorders 
and painful conditions such as rheumatoid arthritis, gout, bursitis, 
painful menstruation, and headache.  
 
Drug Interactions 
 Indomethacin does not directly modify the effect of warfarin, but 
platelet inhibition and gastric irritation increase the risk of bleeding; 
concurrent administration is not recommended. Indomethacin antagonizes 
the natriuretic and antihypertensive effects of furosemide and thiazide 
diuretics and blunts the antihypertensive effect of b receptor antagonists, 
AT1 receptor antagonists, and ACE inhibitors. 
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Adverse Effects 
 A very high percentage (35% to 50%) of patients receiving usual 
therapeutic doses of indomethacin experience untoward symptoms, and 
about 20% must discontinue its use because of the side effects. Most 
adverse effects are dose-related. 
 Gastrointestinal complaints are common and can be serious. 
Diarrhea may occur and sometimes is associated with ulcerative lesions of 
the bowel. Underlying peptic ulcer disease is a contraindication to 
Indomethacin use. Acute pancreatitis has been reported, as have rare, but 
potentially fatal, cases of hepatitis. 
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PROFILES OF POLYMERS EMPLOYED IN THE 
STUDY 
  
 In the present study Tamarind seed polysaccharide (TSP), Guar 
gum, Pectin and Eudragit S100 were used in the preparations of matrix 
tablets. 
Tamarind seed polysaccharide (TSP) 14-16 
Synonyms  
 Tamarind seed polyose, Tamarind gum 
Molecular weight 
 TSP is a polymer with an average molecular weight of 52,350g/mol  
Structural formula 
 It is a galactoxyloglucan mainly of three sugars—glucose, 
galactose, and xylose—in a molar ratio of 3:1:2. 
Description 
 Tamarind gum or Tamarind Seed Polysaccharides (TSP) or 
hydrocolloid is a polysaccharide polymer (D-galactose, D-xylose and D-
glucose) obtained from endosperm of kernels of Tamarind seeds.  Purified 
TSP is a high-molecular-weight, non-ionic, neutral, branched 
polysaccharide consisting of a cellulose-like backbone that carries xylose 
and galactoxylose substituents. Polysaccharides extracted from Tamarind 
seeds are known to produce gels in presence of sugar over a wide pH 
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range. TSP is an interesting candidate for pharmaceutical use, e.g. as a 
carrier of a variety of drugs for controlled release.  
 
Solubility 
 It is insoluble in organic solvents and dispersible in hot water to 
form a highly viscous gel such as a mucilaginous solution with a broad pH 
tolerance and adhesivity. 
 
Safety 
 It is safe to use in food and pharmaceutical formulations as it is a 
plant origin. 
 
Pharmaceutical applications 
 Recently important properties of TSP have been identified. They 
include noncarcinogenicity, mucoadhesivity, biocompatibility and high drug 
holding capacity. These led to its application as excipient in hydrophilic 
drug delivery system. 
• TSP is an interesting candidate for pharmaceutical use, as a carrier 
 of a variety of drugs for controlled release applications. 
• It is used as binder in tablets, gelling agent, thickening agent, as 
 emulsifier and as stabilizer in food, and pharmaceutical industries.  
• As a carrier polysaccharide 
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Guar gum 17, 18 
Non proprietary names 
BP : Guar galactomannan 
PhEur : Guar galactomammanum 
USPNF : Guar gum 
Synonyms 
 E412; Galactorol; Guar flour; Jaguar gum; Mey prodor; Mey   
proguar 
Chemical name and CAS Registry number  
 Galactomannan polysaccharide [9000-30-0] 
Empirical formula  
 (C6H12O6)n 
Molecular weight 
 Guar gum has a molecular weight of 220, 000 g/mol 
Structural formula 
 Guar gum consists of linear chains of (1-4)-β-D-Manno-pyranosyl 
units with α-D-galactopyranosyl units attached by (1-6) linkages and at 
ratio 1:2. 
Description 
 The USPNF 20 describes Guar gum as a gum obtained from the 
ground endosperms of Cyamopsis tetragonolobus. It consists chiefly of 
high molecular weight hydro colloidal polysaccharide, composed of 
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galactan and mannan units combined through glycosidal linkages which 
may be described chemically as galactomannan  
 The main components are polysaccharide composed of D-
galactose and D-mannose in molecular ratio of 1:4 to 1:2. Guar gum 
occurs as an odourless, white to yellowish- white powder with a bland 
taste.  
Solubility 
 It is practically insoluble in organic solvents. In cold or hot water, 
Guar gum disperses and swells almost immediately to form highly viscous 
colloidal dispersion.  
Safety 
 Guar gum is widely used in foods and oral and topical 
pharmaceutical formulations. Excessive consumption may cause gastro 
intestinal disturbance such as flatulence, diarrhoea, nausea.  
 
Pharmaceutical applications  
• Guar gum is a galactomannan commonly used in cosmetics, food    
 products and pharmaceutical formulations. 
• It has also been investigated in the preparation of sustained- 
 release matrix tablets in the place of cellulose derivatives. 
• It has also been examined for use in colonic delivery.      
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Pectin19 
Synonyms 
 Genu Pectin L 200, citrus pectin, Apple pectin, Colyer pectin, 
Mexpectin, Methyl pectin 
Chemical name and CAS Registry number 
 Pectin [9000-69-5] 
Empirical formula 
 (C6H10O7)n 
Molecular weight 
 Pectin has a molecular weight of typically 60–130,000 g/mol. 
Structural formula 
 The characteristic structure of pectin is a linear chain of α-(1-4)-
linked D-galacturonic acid that forms the pectin-backbone, a 
homogalacturonan. 
Description 
 Pectin is a complex mixture of polysaccharides that makes up about 
one third of the cell wall dry substance of higher plants. Much smaller 
proportions of these substances are found in the cell walls of grasses. The 
highest concentrations of pectin are found in the middle lamella of cell 
wall, with a gradual decrease as one passes through the primary wall 
toward the plasma membrane. Although pectin occurs commonly in most 
of the plant tissues, the number of sources that may be used for the 
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commercial manufacture of pectins is very limited. Pectin is a long chain of 
pectic acid and pectinic acid molecules. 
Solubility 
 Pectins are soluble in pure water. Monovalent cation (alkali metal) 
salts of pectinic and pectic acids are usually soluble in water; di- and 
trivalent cations salts are weakly soluble or insoluble. 
Safety 
 Pectins are widely used in food and pharmaceutical formulations as 
it is a plant origin. 
Pharmaceutical applications 
• Pectin has a promising pharmaceutical uses and is presently 
 considered as a carrier material in colon-specific drug delivery 
 systems. 
• Pectin is an interesting candidate for pharmaceutical use, e.g. as a 
 carrier of a variety of drugs for controlled release applications. 
• Many techniques have been used to manufacture the pectin-based 
 delivery systems, especially ionotropic gelation and gel coating. 
 
Chapter 3  Polymer Profile 
 26
Eudragit S100 20 
Non proprietary names 
BP : Methacrylic acid – methyl methacrylate copolymer 
USPNF : Methacrylic acid polymer 
Synonyms 
 Eudragit; kollicot MAE 30 D; kollicot MAE DP; polymeric 
methacrylates 
Chemical names and CAS Registry number  
 Poly (methacrylic acid, methylmethacrylate) 1:2 [25086-15-1] 
Molecular weight 
 Copolymer of methacrylic acid and methyl methacrylate having a 
mean molecular mass about 135,000 g/mol 
Description  
 Methacrylic acid copolymers are anionic copolymerisation products 
of methacrylic acid and methyl methacrylate. The ratio of free carbonyl 
groups to the ester is approximately 1:2. It is readily soluble in neutral to 
weakly alkaline conditions and form salts with alkalis , thus affording film 
costs that are resistant to gastric media , but soluble in intestinal fluid. It is 
a white free flowing powder with at least 95% of dry polymer  
Solubility 
 Soluble in acetone and alcohols, insoluble in dichloromethane and 
petroleum ether 
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Safety 
 It is generally regarded as non toxic and non irritant material. A 
daily in take of 2 mg /kg body weight of Eudragit S100 (equivalent to 
approximately 150 mg for an average adult) may be regarded as 
essentially safe in humans  
Applications in pharmaceutical formulations  
• Polymethacrylates are primarily used in oral capsules and tablet 
 formulations as film coating agent. 
• It is mainly used for enteric coating for solid dosage forms  
• It is used as a binder in both aqueous and organic wet granulation 
 process 
• It may be used in direct compression process in quantities of 10-
 50%. 
Chapter 4  Review of 
Literature 
 28
REVIEW OF LITERATURE 
 Savur et al14 (1947) investigated  the nature of the polysaccharide 
fraction of tamarind seed which show how it differs from pectins, a 
conclusion necessitating revision of the views held to account for many of 
the phenomena of pectin-sugar-acid jelly formation.  They compared 
tamarind seed polysaccharide with fruit pectins by studying the sugar-acid 
jelly formation and various other characters. 
 Taylor et al24 (1985) examined samples of the xyloglucan 
polysaccharide from tamarind seed using X-ray diffraction. Periodicities 
indexing on a spacing of 2.06 nm were observed along the chain direction. 
This value was twice that reported for cellulose and is commensurate with 
four β-1,4- linked glucose residues. Flat, ribbon-like two-fold helical models 
for the β-1,4- linked polyglucose backbone, with two possible schemes for 
decoration with xylose and galactose side groups, were proposed. 
 Hartemink et al21 (1996) studied Fermentation of Xyloglucan, a cell 
wall polysaccharide and part of the dietary fiber fraction of the diet, that 
can be degraded by the intestinal microflora. Selective elimination of 
bacterial groups from faecal slurries indicated that clostridia are the main 
group of intestinal bacteria responsible for degradation of xyloglucan 
polymer. In addition to the polymer-degrading strains, some other strains 
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were able to degrade and ferment oligosaccharides produced from 
tamarind seed. 
 Kirilmaz et al33 (1996) studied the release of Oxolamine citrate 
matrix tablets prepared with direct compression and wet granulation using 
Eudragit RS PM as polymer. The matrix tablets were prepared at drug 
polymer ratio (1:0.5, 1:0.75, 1:1, 1:1.5, 1:2). Drug polymer was found to be 
effective on the release of Oxolamine citrate from matrix tablets. The 
matrix tablets prepared with direct compression technique released drug 
faster than matrix tablets prepared by wet granulation. It was observed 
that release rate of Oxolamine citrate can be decreased by heating the 
matrix tablets prepared by both direct compression and wet granulation 
 Vandamme et al6 (2001) reviewed the use of polysaccharides to 
target drugs to colon to improve the specificity of drug release. Certain 
types of polysaccharides can be used to create the dosage forms. These 
excipients are specially degraded by the colonic microflora and have been 
used for polymer drug conjugates, coatings and matrixing agents. To 
prevent the premature release, these are combined with hydrophobic 
polymers. Authors reviewed the potential uses of polysaccharides, the 
limits and future developments in this field with natural polymers. 
 Sumathi et al23  (2002) studied the sustained release behaviour of 
both water-soluble (acetaminophen, caffeine, theophylline and salicylic 
acid) and water insoluble (indomethacin) drugs from tamarind seed 
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polysaccharide isolated from tamarind kernel powder and the effect of 
incorporation of diluents like microcrystalline cellulose and lactose on 
release of caffeine and partial cross-linking of the polysaccharide on 
release of acetaminophen. The insoluble drug showed near case II or zero 
order release mechanism. The rate of release was in the decreasing order 
of caffeine, acetaminophen, theophylline, salicylic acid and indomethacin. 
An increase in release kinetics of drug was observed on blending with 
diluents. 
 Raghavan et al38 (2002) prepared and evaluated colon specific 
drug delivery systems based on polysaccharides locust bean gum and 
chitosan in the ratio of 2: 3, 3: 2 and 4: 1 using in vitro and in vivo 
methods. The in vitro studies in pH 6.8 phosphate buffer containing 2% 
w/v rat caecal contents showed that the cumulative percentage release of 
mesalazine after 26 h were 31.25±0.56, 46.25±0.96, 97.5±0.26 
(mean±S.D.), respectively. The in vivo studies conducted in nine healthy 
male human volunteers for the various formulations revealed that, the drug 
release was initiated only after 5 h (i.e.) transit time of small intestine and 
the bioavailability of the drug was found to be 85.24±0.10, 196.08±0.12, 
498.62±0.10 µg h/ml 26 (mean±S.D.), respectively. These studies on the 
polysaccharides demonstrated that the combination of locust bean gum 
and chitosan as a coating material proved capable of protecting the core 
tablet containing mesalazine during the condition mimicking mouth to 
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colon transit with a better dissolution profile, higher bioavailability and 
hence a potential carrier for drug targeting to colon. 
 Sinha et al22 (2003) compared on the usual enteric coating 
polymers viz. Eudragit, a cellulose acetate phthalate with shellac and ethyl 
cellulose, as carriers for colon specific drug delivery. Lactose based 
Indomethacin tablets are prepared. These are coated with one of the 
coating polymers to a varying coat thickness. The coated formulations are 
evaluated for dissolution rates under simulated stomach and small 
intestine conditions. From the dissolution data obtained, it was found that 
the dissolution rate varied with the type and concentration of the polymer 
applied. Comparative dissolution data revealed that, of all the various 
polymers and coat thickness used, a 3% (m/m) coat of shellac was most 
suitable for colonic drug delivery.  
 Chourasia et al2 (2003) reviewed various pharmaceutical 
approaches to colon drug delivery systems. The various strategies for 
targeting orally administered drugs to the colon include covalent linkage of 
a drug with a carrier, coating with pH-sensitive polymers, formulation of 
timed released systems, exploitation of carriers that are degraded 
specifically by colonic bacteria, bio adhesive systems and osmotic 
controlled drug delivery systems. Various prodrugs (sulfasalazine, 
ipsalazine, balsalazine and olsalazine) have been developed that are 
aimed to deliver 5-amino salicylic acid (5-ASA) for localized chemotherapy 
Chapter 4  Review of 
Literature 
 32
of inflammatory bowl disease (IBD). Microbially degradable polymers 
especially azo cross linked polymers have been investigated for use in 
targeting of drugs to colon. Certain plant polysaccharides such as 
amylose, inulin, pectin and guar gum remains unaffected in the presence 
of gastrointestinal enzymes and pave the way for the formulation of colon 
targeted drug delivery systems. 
 Tabandeh et al25 (2003) developed a sustained-release tablet 
formulation having proper release profile insensitive to moderate changes 
in tablet hardness that is usually encountered in manufacturing. In this 
study, matrix aspirin (acetylsalicylic acid) tablets with ethylcellulose (EC), 
Eudragit RS100 (RS), and Eudragit S100 (S) were prepared by direct 
compression. The release behaviors were then studied in two counterpart 
series of tablets with hardness difference of three Kp units, and compared 
by non-linear regression analysis. The release pattern for both the S-
containing and RS-containing formulations fitted best in Higuchi model, 
and the proper equations were suggested. In the EC-containing 
formulation, Higuchi and also zero-order models were probable models for 
the release, and a combination equation for the release was suggested. In 
the S-containing formulation, the release profile was completely sensitive 
to the hardness change. In RS-containing series, the slope of the release 
graph did not change due to the hardness decrease, but the y-intercept or 
the lag time in release was decreased. In EC-containing matrix tablets, 
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both the slopes and the y-intercepts did not change by the decrease in 
hardness. In conclusion, EC with an amount as little as 10 percent in 
formulation could make sustained-release aspirin tablets in which the 
release profile is not sensitive to moderate changes in hardness. 
 Momin et al 26 (2004) developed colon targeted drug delivery 
systems for sennosides using guar gum as a carrier. Matrix tablets 
containing various proportions of guar gum (30%-40%) were prepared by 
wet granulation technique using starch paste as a binder. The tablets were 
evaluated for content uniformity and in vitro drug release study as per BP 
method. Guar gum matrix tablets released 4-18% sennosides in the 
physiological environment of gastrointestinal tract depending on the 
proportion of the guar gum used in the formulation. The matrix tablets 
containing 50% of guar gum were found to be suitable for targeting of 
sennosides for local action in the colon. 
 Friend7 (2004) studied on new oral delivery systems for treatment 
of inflammatory bowel disease. Targeted delivery systems for treatment of 
IBD are designed to increase local tissue concentrations of anti-
inflammatory drugs from lower doses compared with systemic 
administration. Delivery systems reviewed rely on temporal control, 
changes in pH along the GIT, the action of local enzymes to trigger drug 
release, and changes in intraluminal pressure. Dissolution of enteric 
polymer coatings due to a change in local pH and reduction of azo-bonds 
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to release an active agent are both used in commercially marketed 
products. Newer approaches showing promise in treating IBD are based 
on polysaccharides. 
 Chaurasia et al39 (2006) prepared guar gum microspheres 
containing  methotrexate characterized for local release of drug in the 
colon, which is a prerequisite for the effective treatment of colorectal 
cancer. Guar gum micros pheres were prepared by the emulsification 
method using glutaraldehyde as a cross-linking agent. The in vitro drug 
release was investigated using a US Pharmacopeia paddle type (type II) 
dissolution rate test apparatus in different media (phosphate-buffered 
saline [PBS], gastrointestinal fluid of different pH, and rat cecal content 
release medium). The drug release in PBS (pH 7.4) and simulated gastric 
fluids followed a similar pattern and had a similar release rate, while a 
significant increase in percent cumulative drug release (91.0%) was 
observed in the medium containing rat cecal content. Guar gum 
microspheres showed adequate potential in achieving local release of drug 
in vitro release studies. 
 Alebiowu et al 14 (2006) studied the influence of Polymer Particle 
size on the release of indomethacin from tamarind seed polyose.  TSP 
was used to prepare sustained-release formulations of indomethacin 
(IND), an anti-inflammatory drug substance with a short half-life of 2.4 ± 
0.4 h.  Its dosage regimen is 25 mg thrice daily, with peptic ulceration as 
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its major side effect. IND is a suitable candidate for a sustained-release 
formulation. Tablets were prepared using direct compression because a 
wet granulation method would cause an initial swelling of the polymer, 
thereby affecting the swelling profile of the various fractions during release 
testing of the matrix tablets. 
 Singh4 (2006) mentioned that solid formulations intended for 
targeted drug release into the lower gastrointestinal (GI) tract are 
beneficial for the localized treatment of several diseases and conditions, 
mainly inflammatory bowel diseases, irritable bowel syndrome and colon 
cancer. This study reviewed on the recent patent literature concerning 
various modified-release (MR) formulation technologies that are claimed to 
provide colonic delivery for a wide array of therapeutic molecules. These 
technologies either utilize a single or a combination of two or more 
physiological characteristics of the colon, which includes pH, microflora 
(enterobacteria), transit time, and luminal pressure. 
 Ghaffari et al 27 (2006) prepared and evaluated theophylline pellets 
with Eudragit RS aqueous dispersions, containing various amounts of 
pectin-chitosan complex and different coating mass gains, using a 
fluidized-bed apparatus. Pellets containing theophylline as a model drug 
and microcrystalline cellulose, in a ratio of 6:4, were prepared by the 
extrusion-spheronization method. Twelve formulations were developed, 
which differed in two factors: coating mass gain (10, 15 and 20%, m/m) 
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and the amount of pectin-chitosan complex (5, 10, 15 and 20%, m/m). 
Twelve formulations were developed, which differed in two factors: coating 
mass gain and the amount of pectin-chitosan complex. Drug release 
studies were conducted using the USP apparatus I (basket) in dissolution 
media, mimicking the conditions prevailing in the stomach, small intestine 
or colon. In formulations with15 or 20% (m/m) of coating mass gain and  
5 or 10% (m/m) of pectin-chitosan, the burst drug release was eliminated 
and replaced by the lag phase of drug release. In the case of burst drug 
release in the colonic medium, formulations with 20% (m/m) of coating 
mass gain and 15 or 20%(m/m) of pectin-chitosan were found to be better 
than the other formulations. 
 Jain et al 3 (2007) studied the ability to deliver drugs to the human 
colon using bio degradable polymers and  a final overview of the various 
approaches to target drugs to the colon utilizing natural polysaccharides, 
the limits and the future developments in this field with these natural 
polymers and . To deliver the compounds in a non-degraded form to the 
lower part of the gastrointestinal tract, they must first of all pass through 
the stomach, the upper part of the intestine and must use the 
characteristics of the colon to specifically release the drugs in this part of 
the digestive tract. Polysaccharidases are bacterial enzymes that are 
available in sufficient quantity in colon to be exploited in colon targeting. 
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 Nasra et al29 (2007) studied on potential of matrix, multilayer and 
compression coated tablets of metronidazole to reach the colon intact has 
been investigated in vitro, using pectin as a carrier. Matrix tablets 
containing various proportions of pectin were prepared by wet granulation 
and direct compression techniques. Multilayer tablets were formulated 
using pectin as release controlling layers, on either side of metronidazole 
matrix tablets. Rapidly disintegrating metronidazole core tablets were 
prepared and compression coated with pectin. The effect of the coat: core 
ratio as well as the incorporation of different percentages of chitosan in the 
pectin coat on drug release was investigated. In vitro release studies 
indicated that matrix and multilayer tablets failed to control the drug 
release in the physiological environment of stomach and small intestine. 
On the other hand, compression coated formulations were able to protect 
the tablet cores from premature drug release, but at high pectin coat: core 
ratios 4: 1 (F13) and 5: 1 (F14). Inclusion of chitosan 3% and 5% w/w 
(F12) in the pectin coat offered better protection at a lower coat: core ratio 
(3: 1). 
 Siepmann et al9 (2007) mentioned in his review that the use of 
polymer blends as coating materials for controlled drug delivery systems 
can offer major advantages, including: (i) facilitated adjustment of desired 
drug release patterns, mechanical properties and drug release 
mechanisms, (ii) improved film formation and storage stability, and (iii) the 
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possibility to develop novel strategies for site specific drug delivery within 
the gastro intestinal tract (e.g., colon targeting). For instance, the blended 
polymers can be incompatible, aqueous polymer dispersions might 
flocculate and plasticizers potentially redistribute from one polymer into the 
other during curing and or long term storage. The author gave an overview 
on the current state of the art of the use of polymer blends as coating 
materials for controlled drug delivery, explaining the major advantages and 
potential pitfalls.  
 Huanbutta et al31 (2008) studied the factors affecting preparations 
of chitosan microcapsules for colonic drug delivery. Chitosan microcores 
containing diclofenac sodium coated with Eudragit S100 were prepared by 
a desolvation technique. Factors affecting morphology, particle size and 
zeta potential of microcapsules was evaluated, i.e. weight ratio of DS: CS: 
ED, surfactant (polysorbate80), anti-adherent (silicon dioxide), and the use 
of sonication or homogenization in preparation processes. Adding of 
polysorbate 80 could not reduce the size of microcapsules; but silicon 
dioxide could reduce the size and aggregation of microcapsules. Finally, 
the use of sonication and homogenization was effective in reducing of the 
size of microcapsules to 53.45±0.63 and 58.72±1.28 micrometers, 
respectively. 
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 Ravi et al32 (2008) developed a novel colon targeted tablet 
formulation using pectin as carrier and Diltiazem HCl and Indomethacin as 
model drugs. The tablets were coated with inulin followed by shellac and 
were evaluated for average weight, hardness and coat thickness. In vitro 
release studies for prepared tablets were carried out for 2 h in pH 1.2 HCl 
buffer, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic fluid. 
The drug release from the coated systems was monitored using UV/Vis 
spectroscopy. In vitro studies revealed that the tablets coated with inulin 
and shellac have limited the drug release in stomach and small intestinal 
environment and released maximum amount of drug in the colonic 
environment. The study revealed that polysaccharides as carriers and 
inulin and shellac as a coating material can be used effectively for colon 
targeting of both water soluble and insoluble drugs. 
 Patel et al34 (2008) prepared and evaluated multiparticulate system 
combining pH-sensitive property and specific biodegradability for colon 
targeted delivery of 5-fluorouracil (5-FU). Study was to prepare and 
evaluate the colon-specific alginate beads of 5-FU for the treatment of 
colon cancer. Calcium alginate beads were prepared by extruding 5-FU 
loaded alginate solution to calcium chloride solution, and gelled spheres 
were formed instantaneously by ionotropic gelation reaction using different 
ratios of FU and alginate, alginate and calcium chloride, stirring speeds 
(500-1500 rpm), and reaction time. The core beads were coated with 
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Eudragit S-100 to prevent drug release in the stomach and provide 
controlled dissolution of enteric coat in the small intestine and maximum 
drug release in the colon. Morphology and surface characteristics of the 
formulation were determined by scanning electron microscopy. In vitro 
drug release studies were performed in conditions simulating stomach to 
colon transit. No significant release was observed at acidic pH, however, 
when it reached the pH where Eudragit S-100 starts to dissolve, drug 
release was observed. 
 Rao et al28 (2003) studied the potential use of pectin in combination 
with two added hydrocolloids, i.e., hydroxy-propyl-methyl cellulose and 
hydroxyethyl cellulose in varied concentrations and coated with ethyl 
cellulose and cellulose acetate phthalate. The results of in vitro drug 
release showed that the matrix tablets prepared with pectin, hydroxyethyl 
cellulose (20 percent) when coated with ethyl cellulose and cellulose 
acetate phthalate were found to be 63.0 percent, 8.4 percent, and 4.5 
percent, respectively, in after eight hours during drug release study period. 
These results were confirmed with the results of roentgenographic studies 
in nine healthy human volunteers to find the shape and integrity of the 
dosage form. The X-ray photographs revealed that the enteric-coated 
tablet was visible only up to 5.5 hours and at the end of eighth hour, the 
photograph has not shown any presence of tablet indicating the loss of 
shape and size by the microflora present in the colon region. So, the 
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results of in vitro and roentgenographic studies revealed that pectin, 
hydroxy ethyl cellulose (20 percent) base coated with ethyl cellulose and 
cellulose acetatephthalate was found to be a promising carrier for 
naproxen to colon. 
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SCOPE AND OBJECTIVE OF THE STUDY 
 
 The site specific delivery of drugs to the colon has implications in 
number of therapeutic areas, which include topical treatment of Crohn's 
disease, Ulcerative colitis, constipation, colorectal cancer, spastic colon 
and irritable bowl syndrome. A colonic delivery system would be 
additionally being valuable when delay in absorption is therapeutically 
desirable in treatment of diseases like rheumatoid arthritis, which are 
influenced by circadian rhythm. These diseases are known to have peak 
symptoms when awakening from night time sleep. 7 
 Various approaches available for colon specific drug delivery 
include (a) coating with pH dependent systems( b) design of timed release 
dosage forms (c) the use of carrier that are degraded exclusively by 
colonic bacteria. The pH dependant systems are designed to release the 
drug to above a particular pH of GIT. The poor site specificity of pH 
dependant systems, because of large variation in the pH of the GIT was 
very well established. The timed release systems release their load after a 
predetermined time period of administration. The site specificity of these 
systems is considered poor because of large variations in gastric emptying 
time and passage across the ileocaecal junction. The best alternative 
approach for colon specific drug delivery is the use of carriers that are 
degraded exclusively by colonic bacteria. The micro flora of colon is in the 
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range of 1010-1012 (CFu/ml) consisting mainly of anaerobic bacteria, e.g. 
Bacteroids, Eubacteria, Clostridia enterococci, Enterobacteria and 
Ruminococcus etc. This vast micro flora fulfils its energy need by 
fermenting various types of substrates that have been left undigested in 
the small intestine e.g. di and tri sacchrides, polysaccharides etc. For this 
fermentation micro flora produces a vast number of enzymes like β-
glucoronidase, β-xylosidase α-arabinosidase, β-galactosidase, nitro 
reductase, azo reductase, deaminase and urea dehydroxylase. Because 
of the presence of the biodegradable enzymes only in the colon, the use of 
the biodegradable polymers for colon specific drug delivery systems is 
considered to be a more site- specific approach as compared to other 
approaches. 8 
 Several studies are published on the use of naturally obtained 
polysaccharides as a carrier in colon targeted drug delivery systems. The 
different polysaccharides that have been evaluated as a carrier for colonic 
drug delivery include pectin30, chitosan27, guar gum26, locust bean gum38, 
inulin and alginates.34 
 Xyloglucan, a cell wall polysaccharide and part of the dietary fiber 
fraction of the diet, can be degraded by intestinal microflora. Clostridia are 
the main group of intestinal bacteria responsible for degradation of 
xyloglucan polymer. It is proposed that xyloglucan is degraded in vivo by 
endo-β-glucanases produced mainly by clostridia, followed by fermentation 
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of the oligosaccharides by a larger group of bacteria. In tamarind seeds 
how ever, xyloglucan is the predominant polysaccharide. 21  
 Although Tamarind seed polysaccharide (TSP) is used as an 
ingredient in food material and in pharmaceuticals, it has not been 
evaluated as carrier for colon targeted drug delivery system. TSP is a 
galactoxyloglucan isolated from seed kernel of Tamarindus indica. 21 
 Indomethacin has been selected as a suitable candidate for this 
study because it is used to treat rheumatoid arthritis, a disease which is 
influenced by circadian rhythm. The disease shows peak symptoms while 
awakening from night time sleep. Therefore a delay in drug release is 
essential in case of Indomethacin.12 
 Studies by Patel and Amol34 have reported the use of a combination 
of natural polysaccharide and pH dependant system as a best choice of 
carrier for targeting drugs to the colon.  
 The present investigation is aimed at evaluating suitability of a 
combination of naturally occurring polysaccharide obtained from 
Tamarindus indica seed and Eudragit S100 as a carrier for colon targeted 
drug delivery system. 
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EXPERIMENTAL WORK 
MATERIALS USED 
• Indomethacin 
 Gift sample from Microlabs Pvt Ltd, Banglore, India 
• Guar gum  
 Hi media Laboratories, Mumbai 
• Pectin  
 Hi media Laboratories, Mumbai  
• Eudragit S100 
 Roehm Pharma Polymers, Darmstadt, Germany 
• Petroleum ether 
 Qualigens Fine Chemicals, Lucknow 
• Diethyl ether 
 Qualigens Fine Chemicals, Lucknow 
• Starch 
 Hi media Laboratories, Mumbai 
• Lactose 
 S.d Fine Chemicals, Mumbai 
• Methanol  
 Qualigens Fine Chemicals, Lucknow 
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INSTRUMENTS AND EQUIPMENTS USED 
• UV Visible spectrophotometer  
 Jasco V-530 double beam 
• Dissolution test apparatus USP  
 Tab Machines, Mumbai 
• Tablet compression machine 
 Rimek mini press-1 
 
Table 2: Formulation codes for Indomethacin matrix tablets 
Formulation code Polymer concentration (%) 
G1F1 TSP(30)+Eudragit S100(30) 
G1F2 TSP(40)+Eudragit S100(30) 
G1F3 TSP(50)+Eudragit S100(30) 
G1F4 TSP(60)+Eudragit S100(30) 
G1F5 TSP(70)+Eudragit S100(30) 
G2 Guar gum(50)+Eudragit S100(30) 
G3 Guar gum(50)+pectin(35)+Eudragit S100(30) 
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METHODS 
Isolation of Tamarind Seed Polysaccharide (TSP) 23 
 Tamarind seed polysaccharide was prepared following methods by 
Rao et al., in three batches on a laboratory scale. To 20g of tamarind 
kernel powder, 200ml of cold distilled water was added and slurry was 
prepared. The slurry was poured into 800ml of boiling distilled water. The 
solution was boiled for 20 minutes under stirring condition in a water bath. 
The resulting thin clear solution was kept overnight so that most of the 
proteins and fibers settled out. The solution was then centrifuged at 5000 
rpm for 20 minutes. The supernatant was separated and poured into twice 
the volume of absolute ethanol by continuous stirring. The product was 
pressed between felt. The precipitate was washed with absolute ethanol, 
diethyl ether and petroleum ether and then dried at 50-60°C under 
vacuum. The dried material was ground and sieved to obtain granules of 
different particle size range.23 
 
Characterization of TSP by X-ray diffraction24 
 Diffraction pattern of powdered TSP sample was recorded With a 
Bruker AXS D8 Advance X ray diffractometer. (STIC/SF/2008-09/1813). 
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PREPARATION OF INDOMETHACIN MATRIX TABLETS CONTAINING 
TSP AND EUDRAGIT S100 AS CARRIERS  
 Matrix tablets of Indomethacin were prepared by wet granulation 
method. Lactose was used as a diluent and a mixture of talc and 
magnesium stearate was added as lubricant. Tamarind seed 
polysaccharide (TSP) (50%) and Eudragit S100 (30%) was included in 
formulations.25 The composition of the matrix formulations used in the 
study containing 25 mg of Indomethacin is shown in table 3. 
 TSP was sieved separately and mixed with Indomethacin and 
lactose. Powders were blended and granulated using 10% starch paste. 
The wet mass was passed through mesh (10#) and granules were dried at 
50°C for 30 minutes. The dried granules were passed through mesh (20#) 
and these granules were lubricated with mixture of magnesium stearate 
and talc (2:1). The lubricated granules were compressed using round, flat 
and plain punches using Rimek mini press -1 machine. 26  
 Matrix formulations of Indomethacin with varying concentrations of 
TSP ranging from 30% to 70% along with Eudragit S 100 (30%) also 
prepared in different batches in order to identify the formulation with the 
best release profile. Composition of these matrix formulations are given in 
table 3. 
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Table 3: Composition of matrix tablets of Indomethacin with varying 
concentrations of TSP ranging from 30% to 70% along with Eudragit 
S100 (30%) 
Quantity (mg) present in each tablet 
Ingredients 
G1F1 G1F2 G1F3 G1F4 G1F5 
Indomethacin 25 25 25 25 25 
TSP 69.5 95 120 145 192 
Eudragit S100 69.5 69.5 69.5 75 82 
Lactose 80 54.5 29.5 5 5 
Talc 4 4 4 4 4 
Magnesium 
stearate 2 2 2 2 2 
Total weight 250 250 250 256 310 
 
PREPARATION OF INDOMETHACIN MATRIX TABLETS CONTAINING 
GUAR GUM+EUDRAGIT S100 AND GUAR GUM+PECTIN+EUDRAGIT 
S100 AS CARRIERS  
 The formulation with the best drug release profile identified from the 
above batch were then compared with the drug release profile of 
Indomethacin matrix tablets prepared using a) Guar gum +Eudragit S100 
and b) Guar gum+ Pectin+Eudragit S100.30 Composition of these matrix 
formulations are shown in table 4 and 5 
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Table 4: Composition of matrix tablet of Indomethacin containing 
Guar gum (50%) and Eudragit S100 (30%) 
Ingredients Quantity (mg) present in tablet 
Indomethacin 25 
Eudragit S100 69.5 
Guar gum 120 
Lactose 23.5 
Talc 4 
Magnesium stearate 2 
Total weight 250 
 
Table 5: composition of matrix tablet of Indomethacin containing 
Guar gum (50%), Pectin (35%) and Eudragit S 100(30%) 
Ingredients Quantity (mg) present in tablet 
Indomethacin 25 
Eudragit S100 60 
Guar gum 120 
Pectin 74 
Lactose 5 
Talc 4 
Magnesium stearate 2 
Total weight 290 
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EVALUATION OF MATRIX TABLETS 36 
 Hardness and friability of the matrix tablets formulated were 
evaluated using a Pfizer hardness tester and a Roche friabilator 
respectively. For friability, test 20 tablets were taken and weight was 
determined. Then they were placed in friabilator and allowed to make 100 
revolutions. Tablets were then dedusted and reweighed. To test hardness 
of tablets, 5 tablets were taken from each batch and subjected to test.  
Disintegration time of the tablets was determined in tablet disintegration 
test machine. 
 
Determination of drug content 11 
 Indomethacin matrix tablets were tested for their drug content by 
Indian pharmacopeia method. A quantity of powdered contents of 10 
tablets equivalent to 50 mg of Indomethacin was weighed accurately 
and10 ml of water was added and allowed to  stand for 10 minutes, with 
occasional shaking.  75 ml methanol was added, shaken well, and added 
sufficient methanol to produce 100 ml and then filtered. To 5 ml filtrate 
sufficient mixtures of equal volumes of methanol and 7.2 phosphate buffer 
was added to produce 100 ml. Absorbance was measured at 318 nm. 
Drug content of Indomethacin was calculated. 
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STANDARD GRAPH OF INDOMETHACIN 
Preparation of stock solution  
 100 mg of Indomethacin is dissolved in 100ml of ethanol to get a 
concentration of 1000 µg/ml. 
 From this 10 ml was taken and made up to 100 ml with ethanol to 
get a concentration of solution 100 µg/ml. 
Preparation of various concentrations of drug solution 
1. 1 ml of stock solution was made up to 10 ml with ethanol to give  
10 µg/ml  
2. 2 ml of stock solution was made up to 10 ml with  ethanol to give 
20µg/ml 
3. 3 ml of stock solution was made up to 10 ml with ethanol to give  
30 µg/ml 
4. 4 ml of stock solution was made up to 10 ml with ethanol to give  
40 µg/ml 
5. 5 ml of stock solution was made up to 10 ml with ethanol to give  
50 µg/ml 
Procedure 
 Various concentrations of Indomethacin (10, 20, 30, 40 and  
50 µg/ml) were prepared as mentioned above. Absorbance of the solution 
was measured against reagent blank at 318 nm using UV 
spectrophotometer. A standard graph between concentrations vs. 
absorbance was plotted. A straight line passing through origin was 
obtained. 
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PREPARATION OF BUFFER SOLUTIONS 37 
Hydrochloric acid (0.1N) 
 8.5 ml of concentrated Hydrochloric acid was added to 1000 ml 
volumetric flask and made up to the volume with distilled water.  
 
Phosphate buffer pH 7.4 
 50 ml of 0.2 M Potassium dihydrogen phosphate is taken in a  
200 ml of volumetric flask and 39.1 ml of 0.2 M Sodium hydroxide was 
added and made up to the volume with distilled water. 
 
Phosphate buffer pH 6.8 
 50 ml of 0.2 M Potassium dihydrogen phosphate was taken in a 200 
ml of volumetric flask and 22.4 ml of 0.2 M Sodium hydroxide was added 
and made up to the volume with distilled water. 
 
Chapter 6  Experimental Work 
 54
IN VITRO DRUG RELEASE STUDIES 26-32  
 The ability of matrix tablets of Indomethcin (containing TSP and 
Eudragit S100 as carriers) to remain intact in the physiological 
environment of stomach and small intestine was assessed by mimicking 
mouth to colon transit. Drug release studies were carried out using USP 
XXIII dissolution apparatus (100 rpm, 37± 0.5°C) in 900 ml 0.1N 
Hydrochloric acid for 2 hours as the average gastric emptying time is ~2 h. 
The dissolution medium was replaced with 900ml pH 7.4 phosphate buffer 
and tested for 3 hours as the average small intestinal transit time is about 
3 hours. The dissolution medium was then replaced with pH 6.8 phosphate 
buffer and drug release studies were carried out for 24 hours as the usual 
colonic transit time is 20-30 hours. 10 ml of sample was taken at the end 
of specified time intervals filtered and filtrate was analysed for 
Indomethacin at 318nm using UV spectrophotometer. A 10 ml volume of 
filtered, fresh dissolution medium was added to make the volume after 
each sample withdrawal. 26 
 Matrix formulations of Indomethacin with varying concentrations of 
TSP ranging from 30% to 70% along with Eudragit S100 (30%) were 
prepared in different batches in order to identify the formulation with the 
best release profile. Composition of these matrix formulations are given in 
table 2. The formulation with the best drug release profile identified from 
the above batch were then compared with the drug release profile of 
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Indomethacin matrix tablets prepared using a)Guar gum(50%)+Eudragit 
S100 (30%)and b)Guar gum(50%)+Pectin(35%)+Eudragit S100(30%). 
Composition of these matrix formulations are shown in table 3 and 4. The 
above procedure was followed in order to carryout the drug release 
studies for these formulations. 
 
STATISTICAL ANALYSIS 
 The mean percentage of Indomethacin released from TSP 
(50%)+Eudragit S 100(30%) matrix formulation in pH 6.8 phosphate 
buffered solution was compared with that of drug released from 
formulations containing a)Guar gum+Eudragit and b)Guar 
gum+Pectin+Eudragit. Paired t test was used to find the statistical 
significance. P value < 0.05 is considered statistically significant. 
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RESULTS AND DISCUSSION 
 X-ray diffraction analysis – x-ray diffraction pattern (figure 3) of 
TSP did not show any characteristic peak, which indicate that the structure 
is completely amorphous. The result confers with the x-ray diffraction 
study of Tamarind seed polysaccharide by Sumathi et al.23 The result 
show that the isolated polysaccharide has similar behaviour with that 
reported by others. This isolated polysaccharide along with Eudragit S100 
was used in preparation of matrix tablets of Indomethacin. 
 The present study was aimed at developing and evaluating matrix 
tablet of Indomethacin for colon targeting using a combination of Tamarind 
seed polysaccharide and Eudragit S100 as a matrixing agent. The tablet 
formulation released decreased amount of Indomethacin in physiological 
environment of stomach and small intestine. Majority of the drug was 
released in pH 6.8 phosphate buffer, which is the pH prevailing in the 
colon. 
 Since TSP was found to have poor flow characteristics and was to 
be incorporated in large amounts in matrix tablets Indomethacin tablets 
were prepared by wet granulation method using 10% starch paste as 
binder. The diameter and thickness of tablets were 6.5mm and 2mm 
respectively. The result of hardness test, friability, disintegration test and 
drug content shown in table 7. 
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 The matrix tablets were subjected to in vitro drug release study in 
0.1 N HCl (2hours), pH 7.4 phosphate buffer saline (3 hours) and pH 6.8 
phosphate buffer saline (24 hours). All the formulations showed no drug 
release in first 2 hours in stimulated gastric environment (0.1N HCl). The 
cumulative percentage drug release in pH 7.4 buffer is shown in table 8 to 
10 and figure 5 and 6. 
 Table 11 to 13 and figure 7 and 8 illustrate the cumulative 
percentage drug release of all matrix formulations in pH 6.8 buffer. 
 From figure 6 it was clear that small quantity of drug (G1F3 - 
28.72%, G2 - 22.13%, G3 - 30.1%) was released in pH 7.4 and majority of 
drug was released in pH 6.8 PBS buffer. 
 Tablets of G1F3 released 82.35 % of Indomethacin in pH 6.8 buffer 
solution; G2 released 75.95%; G3 released 87.11% at 24 hours. 
              On comparing formulation G1F3 (TSP 50%+ Eudragit S100 30%) 
with G2 (Guargum 50%+ Eudragit S100 30%) using Paired t- test, the 
difference in the amount of drug released after 24 hours of dissolution 
study was not statistically significant, while a statistically significant 
difference in the amount of drug released was observed on comparing 
G1F3 (TSP50% + Eudragit S10030%) with G3 (Guar gum 50% + Pectin 
35% + Eudragit S100 30%).   
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 The present study revealed that a combination of Tamarind seed 
polysaccharide and Eudragit S100 may be considered as a potential 
candidate for targeting drugs to colon. But further studies are warranted 
using rat caecal contents as TSP undergoes degradation in colon by 
colonic bacteria. Further in vivo studies using healthy human volunteers 
may be required in order to establish various pharmacokinetic parameters 
of Indomethacin matrix tablets containing TSP (50%) and Eudragit S100 
(30%). 
 
 
Chapter 7 Results & Discussion 
 
 59
Fig. 3: X-ray diffraction pattern of Tamarind seed polysaccharide 
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Table 6: Calibration Data for the estimation of Indomethacin 
(10-50 µg/ml) 
 
S. No. Concentration in µg/ml Absorbance at 318 nm 
1 0 0.000 
2 10 0.2630 
3 20 0.4600 
4 30 0.6500 
5 40 0.8754 
6 50 1.1338 
 
 
 
Fig. 4: Calibration curve for estimation of Indomethacin 
 (10-50 µg/ml) 
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Table 7: Evaluation of Indomethacin matrix tablets 
Evaluation of 
tablets G1F1 G1F2 G1F3 G1F4 G1F5 G2 G3 
Crushing strength 
(kg/cm2) 4.6 5.1 5.3 4.9 5.1 4.7 5.2 
Friability (%) 0.39 0.32 0.45 0.43 0.39 0.46 0.42 
Drug content (%) 103 101 102 103 101 98 102 
Disintegration (min) 18 15 15 18 14 16 16 
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In vitro Drug Release Studies 
Table 8: Cumulative percent drug release from Indomethacin 
tablets containing various concentrations of TSP (30- 70%) + 
Eudragit S100 (30%) in pH 7.4 buffer 
 
Percentage release of Indomethacin (%) Time in 
minutes G1F1 G1F2 G1F3 G1F4 G1F5 
30 6.30 8.63 12.3 5.88 4.10 
60 11.98 13.68 15.84 9.38 7.94 
90 15.10 17.70 18.92 13.56 10.12 
120 17.68 19.34 22.64 15.57 12.51 
150 18.56 22.82 25.62 16.98 13.83 
180 24.12 26.36 28.72 20.12 15.68 
 
Fig. 5: Comparison of release profiles of Indomethacin from 
matrix formulations containing varying concentrations of TSP  
(30-50%) + Eudragit S100 (30%) in pH 7.4 phosphate buffer 
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Table 9: Cumulative percent drug release from Indomethacin 
tablets containing Guar gum (50 %) + Eudragit S100 (30%) in  
pH 7.4 Buffer 
 
Time in minutes Percentage release of Indomethacin from G2 (%) 
30 11.56 
60 12.60 
90 13.2 
120 13.7 
150 14.56 
180 22.13 
 
Table 10: Cumulative percent drug release from Indomethacin 
tablets containing Guar gum (50%) + Pectin (35%) + Eudragit S100 
(30%) in pH 7.4 Buffer 
 
Time in minutes Percentage release of indomethacin from G3 (%) 
30 15.20 
60 18.63 
90 23.40 
120 25.45 
150 28.56 
180 30.10 
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Fig 6: Comparison of release profiles of Indomethacin from matrix 
formulations G2, G3, and G1F3 in pH 7.4 phosphate buffer 
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Table 11: Cumulative Percent Drug release from Indomethacin 
matrix tablets containing various concentrations of TSP (30- 70%) 
+ Eudragit S100 (30%) in pH 6.8 buffer 
 
PERCENTAGE RELEASE OF INDOMETHACIN (%) 
TIME IN Hrs 
G1F1 G1F2 G1F3 G1F4 G1F5 
1 8.10 13.40 20.10 12.53 15.93 
2 12.50 18.90 25.25 17.89 19.20 
3 20.30 25.30 35.95 24.81 25.75 
4 28.90 32.30 52.34 29.52 30.93 
5 35.20 38.50 55.12 36.89 38.43 
6 38.40 45.50 59.73 42.23 44.33 
7 40.21 50.60 65.47 48.93 50.92 
8 48.35 55.23 68.23 54.25 56.29 
24 72.30 75.45 82.35 75.24 77.47 
 
Fig 7: Comparison of release profiles of Indomethacin from matrix 
formulations containing varying concentrations of TSP (30-50%) + 
Eudragit S100 (30%) in pH 6.8 phosphate buffer 
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30
Time in Hrs
C
um
ul
at
iv
e 
Pe
rc
en
ta
ge
 R
el
ea
se
G1F1 G1F2 G1F3 G1F4 G1F5  
 
Chapter 7 Results & Discussion 
 
 66
Table 12: Cumulative percent drug release from Indomethacin 
tablets containing Guar gum (50 %) + Eudragit S100 (30%) in  
pH 6.8 Buffer 
 
Time in hrs Percentage release of Indomethacin from G2 (%) 
1 36.8 
2 46.20 
3 47.23 
4 48.72 
5 51.52 
6 55.56 
7 60.82 
8 64.65 
24 75.95 
 
Table 13: Cumulative percent drug release from Indomethacin 
tablets containing Guar gum (50%) + Pectin (35%) + Eudragit S100 
(30%) in pH 6.8 Buffer 
 
Time in hrs Percentage release of indomethacin from G3 (%) 
1 11.9 
2 20.26 
3 23.70 
4 44.72 
5 45.11 
6 47.23 
7 53.18 
8 60.14 
24 87.11 
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Fig 8: Comparison of release profiles of Indomethacin from matrix 
formulations G2, G3, and G1F3 in pH 6.8 phosphate buffer  
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CONCLUSION 
 
  The present study was carried out to develop colon targeted drug 
delivery system for Indomethacin using a combination of Tamarind seed 
polysaccharide (TSP) and Eudragit S100 as carriers. Matrix tablets 
containing varying concentration (30%- 70%) of TSP along with 30% 
Eudragit S100 were prepared by wet granulation method and subjected to 
in vitro drug release studies. Matrix tablets containing 50% TSP and 30% 
Eudragit S100 was found to release the maximum amount of drug 
(82.35%) after 24 hour of dissolution study. Drug release achieved from 
matrix tablets containing a) Guar gum (50%) + Edragit S100 (30%) and b) 
Guar gum (50%) + Pectin (35%) + Eudragit S100(30%) was 75.9% and 
87.1% respectively. Though there was statistically significant difference in 
the amount of drug released from these formulations, a combination of 
TSP and Eudragit S100 may be considered as a potential candidate for 
targeting Indomethacin to colon. 
  
 
List Of Tables 
Table 
no. 
Title Page 
no. 
   
1 Relevant drugs for colon- specific 
associated diseases 
    
2 Formulation code for the matrix 
formulations 
    
3 Composition of matrix tablets of 
Indomethacin with varying 
concentrations of TSP ranging from 
30% to 70% along with Eudragit S100 
(30%) 
    
4 Composition of matrix tablet of 
Indomethacin containing Guar gum 
(50%) and Eudragit S100 (30%) 
    
5 Composition of matrix tablet of 
Indomethacin containing Guar gum 
(50%), Pectin (35%) and Eudragit S 
100(30%) 
    
6 Calibration Data for the estimation of 
Indomethacin 
    
7 Evaluation of Indomethacin matrix 
tablets 
    
8 Cumulative percent drug release from 
Indomethacin tablets containing 
various concentrations of TSP (30- 
70%) + Eudragit S100 (30%) in pH 7.4 
buffer 
    
9 Cumulative percent drug release from 
Indomethacin tablets containing Guar 
gum (50 %) + Eudragit S100 (30%) in 
pH 7.4 Buffer 
    
Table 
no. 
Title Page 
no. 
   
10 Cumulative percent drug release from 
Indomethacin tablets containing Guar 
gum (50%) + Pectin (35%) + Eudragit 
S100 (30%) in pH 7.4 Buffer 
    
11 Cumulative Percent Drug release from 
Indomethacin matrix tablets containing 
various concentrations of TSP (30- 
70%) + Eudragit S100 (30%) in pH 6.8 
buffer 
    
12 Cumulative percent drug release from 
Indomethacin tablets containing Guar 
gum (50 %) + Eudragit S100 (30%) in 
pH 6.8 Buffer 
    
13 Cumulative percent drug release from 
Indomethacin tablets containing Guar 
gum (50%) + Pectin (35%) + Eudragit 
S100 (30%) in pH 6.8 Buffer 
    
 
  References 
REFERENCES 
 
1. Aurora J, Naresh T, Vinayak P. Colonic drug delivery and 
opportunities-an overview. European Gastroenterology Review 
2006; (current issues):1- 4. 
2. Chourasia MK, SK Jain. Pharmaceutical approaches to colon 
targeted drug delivery systems. J Pharm Pharmaceut Sci 2003 Feb 
3;6(1):33-66. 
3. Jain A, Yashwant G, Sanjay KJ. Perspectives of biodegradable 
natural polysaccharides for site-Specific drug delivery to the Colon. 
J Pharm Pharmaceut Sci 2007 April 18; 0(1):86-128. 
4. Singh BN. Modified-Release Solid formulations for colonic delivery. 
recent patents on drug delivery & ofrmulation 2007;1:53-63. 
5. Ibekwe VC, Richard AK, Abdul WB. Drug delivery to the colon. The 
drug delivery companies report 2004; (technology/ industry 
overviews):27-30. 
6. Vandamme F, Lennoury A, charrueau C, Chaumeil JC. The use of 
polysaccharides to target drugs to colon. Carbohydrate polymers 
2002;48:219-231.  
7. Friend DR. New oral delivery systems for treatment of inflammatory 
bowl disease. Advanced drug delivery reviews 2005;(57):247-265. 
  References 
8. YSR K, Seetha DA, Nageshwara RL, Baskar RPR, Karthikeyan RS, 
Satyanarayan V. Guar gum as a carrier for colon specific delivery ; 
influence of metronindazole and tinindazole on invitro release of 
albendazole from Guar gum matrix tablets. J Pharm pharmaceutic 
sci 2001;4(3):235-243. 
9. Siepmann F, Siepmann J, Walther M, Macrae RJ, Bodmeier 
R.Polymer blends for controlled release. Journal of Controlled 
Release 2008;(125):1-15.  
10. Noreen F, Tehseen A, Amina M, Saima N. spectrophotometric 
determination of indomethacin using partial least square method. 
Proc Pakistan Acad Sci 2007; 44(3):173-179. 
11. Indian pharmacopeia, 3rd ed. Indian pharmacopeia commission. 
New Delhi: Ministry of health and family welfare, Govt of India; 
1996. p. 393-4. 
12. Roger W, Clive E, editors. Clinical pharmacy and Therapeutics. 3rd 
ed. London: Churcil Livingstone; 2003. p. 791-797. 
13. Tripathi KD. Essentials of medical pharmacology. 6th ed. Mumbai: 
Jaypee Brother Medical Publishers LTD;2008. p. 184,195,200,206.  
14. Savur GR, A Sreenivasan. Isolation and characterization of 
Tamarind seed polysaccharide. Journal of biological chemistry 
1947;501-509. 
  References 
15. Alebiowu G, Madhu K, Sathyawan S. Polymer Particle Size 
Influence on Indomethacin Release from Tamarind Seed Polyose: 
A Potential Sustained-Release Excipient. [Online]. 2006 [cited 2008 
Aug 14]; Available from:http://www.pharm tech.com 
16. Kulkarni D, Dwivedi AK, Sarin JPS, Singh S. Tamarind seed 
polyose: a potential polysaccharide for sustained release of 
verapamil hydrochloride as model drug. Indian Journal of 
Pharmaceutical Sciences 1997 Jan-Feb;59(1):1-7.  
17. Raymond CR, Paul JS, Paul JW. Hand book of pharmaceutical 
excipients. 4th ed. Bombay: KM Varghese Company. p. 272-3 
18. Natural products. Guar gum. [Online]. [cited 2006 Jul 12]. Available 
from:http://www.drugs.com/naturalproducts/guargum/index.html  
19. Natural products. Pectin. [Online]. [cited 2006 Jul 12]. Available 
from: http://en.wikipedia.org/wiki/Pectin/index.html 
20. Specifications and test methods Eudragit L100 and Eudragit S100 
2004:1-4. 
21. Hartermink R, Vanlaere KMJ, Mertens AKS, Rombouts FM. 
Fermentation of xyloglucan by intestinal bacteria. Anaerobe 
1996;(2):223-230. 
22. Sinha VR, Rachana K. Coating polymers for colon specific drug 
delivery:A comparative in vitro evaluation. Acta Pharm 
2003;(53):41-47. 
  References 
23. Sumathi S, Alok RR. Release behaviour of drugs from Tamarind 
Seed polysaccharide tablets. J Pharm Pharmaceut Sci 2002 Mar 
7;5(1):12-18. 
24. Taylor EP, Edward DT. X-ray diffraction studies on the xyloglucan 
from Tamarind seed. FEBS 1985;181(2):300-302. 
25. Tabandeh H, Seyed AM, Tina BG. Preparation of sustained-release 
matrix tablets of Aspirin with Ethylcellulose, Eudragit RS100 and 
Eudragit S100 and studying the release profiles and their sensitivity 
to tablet hardness.[Online] Tehran: School of pharmacy, Shaheed 
Beheshti University of Medical sciences and Health services; 
2003.Available from: http://www.ijpronline.com/Docs/20034/IJPR 
182.htm [cited 2008 jul 12].  
26. Momin M, K Pundarikakshudu. In vitro studies on Guar gum based 
formulation for the colon targeted delivery of Sennosides. J Pharm 
Pharmaceut Sci 2004;7(3):325-331. 
27. Gaffari A, Mahvash O, Kamran H, Khosrow B, Morteza RT. 
Pectin/chitosan/Eudragit RS mixed-film coating for bimodal drug 
delivery from theophylline pellets: Preparation and evaluation. Acta 
Pharm 2006;(56):299-310. 
  References 
28. Rao KP, Prabhasankar B, Ashok K, Azeemuddhin K, Biradhar SS, 
Patil SS et al. Formulation and Roentgenographic Studies of 
Naproxen-pectin-based Matrix Tablets for Colon Drug Delivery. 
Yale Journal of Biology and Medicine 2003;(76):149-154. 
29. Nasra MA, EL-Massik MA, Naggar VF. Development of 
metronidazole colon-specific delivery systems. systems/Asian 
Journal of Pharmaceutical Sciences 2007;2(1);18-28. 
30. Paharia A, Awesh KY, Gopal R, Sunil KJ, Shyam SP, Govind PA. 
Eudragit-coated pectin microspheres of 5-Fluorouracil for colon 
targeting. AAPS PharmSciTech 2007; 8(1):E1-E7. 
31. Huanbutta K, Manee LA, Pornsak S, Sonthaya L, Satit P,Jurairat 
N.Factors affecting preparations of chitosan micro capsules for 
colonic drug delivery. Journal of Metals, Materials and Minerals 
2008;18(2):79-83.s  
32. Ravi V, Pramod Kumar TM, Siddaramaiah. Novel colon targeted 
drug delivery system using natural polymers. Indian J Pharm Sci 
2008; 70 (1):111-113. 
33. Kirilmaz L, Cigidem D. Studies on the release of oxolamine citrate 
from matrix tablets prepared with Eudragit. Actapharmaceutica 
Turcica 1996;1970(1):5-8. 
  References 
34. Patel HK, Amrita N, Murthy RSR. Characterization of calcium 
alginate beads of 5-fluorouracil for colon delivery. Asian J Pharm 
2008;2(4):241-245.  
35. Munira M, Pundarikakshudu k, Nagori SA. Design and development 
of mixed film of pectin: ethyl cellulose for colon specific drug 
delivery of sennosides and triphala. Indian J Pharm Sci 
2008;70(3):338-343. 
36. Leon L, Herbert AL, Joseph LK. The theory and practice of 
industrial pharmacy. 3rd ed. Bombay: Varghese publishing 
house;1987.p. 88,299,313,320,328. 
37. Indian pharmacopeia, 3rd ed. Indian pharmacopeia commission. 
New Delhi: Ministry of health and family welfare, Govt of India; 
1985. p. A142. 
38. Raghavan VC, Chithambaram M, Joseph A, Josephine LJ, 
Thengungal KR. In vitro and in vivo Investigation into the Suitability 
of BacteriallyTriggered Delivery System for Colon Targeting. Chem. 
Pharm. Bull 2002;50(7):892-895. 
39. Chaurasia M, Manish KC, Nithin KJ, Aviral J, Vandhana 
S,Yashwant G et al. Cross-linked Guar gum Microspheres: A viable 
approach for improved delivery of anticancer drugs for the 
treatment of colorectal Cancer. AAPS PharmSciTech  
2006;7(3):E1-E9. 
  References 
40. Saeio K, Yanee P, Helmut V, Siriporn O. Factors influencing drug 
dissolution characteristic from hydrophilic matrix tablet. Sci pharm 
2007;(75):147-163. 
41. Li J, Libo Y, Sheila MF, Tom JH, Shunsuke W, Masataka K, Joseph 
AF. In vitro evaluation of dissolution behavior for a colon-specific 
drug delivery system (CODES™) in multi-pH media using United 
States Pharmacopeia apparatus II and III. AAPS PharmSci Tech 
2002; 3(4): 1-8. 
